Registry of Patients With Remote Posterior cErebral Hemorrhage Following Reperfusion Treatment in Ischemic Stroke
NCT ID: NCT05871528
Last Updated: 2023-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2021-05-01
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Main Objectives
* To explore the frequency and risk factors for intracranial hemorrhage during follow-up of patients with remote cerebral hemorrhage.
* To explore the frequency and progression of cognitive deterioration during follow-up in patients with remote cerebral hemorrhage.
Methodology Observational, prospective, multicenter registry with a population-based case-control design of consecutive patients with remote hemorrhage following reperfusion therapy in acute ischemic stroke. Inclusion criteria: Diagnosis of ischemic stroke with age greater than or equal to 18 years who has remote cerebral hemorrhage after receiving reperfusion therapy in the acute phase. Exclusion criteria: Lack of basic data (age, sex, neuroimaging data) or telephone for follow-up. The cases will be those patients with remote hemorrhage. For each case included, 4 consecutive controls will be included (2 with local parenchymal hemorrhagic transformation and 2 without hemorrhagic transformation). The data will be filled out within the (Codi Ictus de CATalunya) CICAT registry form (currently mandatory in all stroke centers in Catalonia) to which additional variables will be added. Telephone follow-up will be conducted at 3, 12, and 24 months.
Main study variable:
* Any type of spontaneous or traumatic intracranial hemorrhage during a 24-month follow-up.
* Score on the "Short Informant Questionnaire" scale (a validated 17-question questionnaire to be conducted over the phone, where a score higher than 57 points indicates cognitive impairment).
Expected sample size during a 2-year recruitment period: 105-300 patients (considering the participating centers to date).
Additional information. This study is endorsed by the "Pla Director de la Malaltia Vascular Cerebral" in Catalonia.
Participating Centers. Participation offers have been sent to the 28 hospitals in the hospital network of Catalonia with the capacity to administer intravenous fibrinolysis. Positive responses have been received from 13 of them so far. In case the project is accepted by the (Comité Ético de Investigación Clínica) CEIC Sant Pau, the centers that have not responded will be contacted again to obtain their participation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Study of Intracerebral Hemorrhage Patients in Hospital Parc Taulí
NCT04877405
Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompressive Hemicraniectomy
NCT05847699
Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage
NCT06375889
Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
NCT02893631
Brain Hemorrhage and Functional Outcome in Stroke Patients With CAA Features on Pre-thrombolysis MRI Treated With Intravenous Thrombolysis (Thrombolysis in CAA) ( Thromb in CAA )
NCT05565144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No hemorrhagic transformation
Patients with ischemic stroke treated with intravenous thrombolysis and no hemorrhagic transformation (IH1 or IH2 are allowed)
No interventions assigned to this group
Local hemorragic transformation
Patients with ischemic stroke treated with intravenous thrombolysis and hemorrhagic transformation PH1 or PH2
No interventions assigned to this group
Remote hemorrhage
Patients with ischemic stroke treated with intravenous thrombolysis and remote hemorrhage in areas without evident ischemia (rPH)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18 or older
3. Definite diagnosis of ischemic stroke (intracranial large vessel occlusion, compatible lesion on neuroimaging)
4. Administration of a fibrinolytic drug associated or not with endovascular therapy (intravenous or local)
5. Availability of a control brain imaging before the first 36 hours from reperfusion treatment.
Exclusion Criteria
18 Years
102 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Germans Trias i Pujol Hospital
OTHER
Hospital del Mar
OTHER
Hospital de Granollers
OTHER
Hospital Arnau de Vilanova
OTHER
Parc Taulí Hospital Universitari
OTHER
Consorci Sanitari del Garraf
OTHER
Hospital de Sant Joan Despí Moisès Broggi
OTHER
Hospital Clinic of Barcelona
OTHER
University Hospital of Girona Dr. Josep Trueta
NETWORK
Hospital Universitari de Bellvitge
OTHER
Hospital Vall d'Hebron
OTHER
Agència de Qualitat i Avaluació Sanitàries
OTHER_GOV
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luis Prats Sanchez, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIBSP-HER-2020-79
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.